Fig. 4
From: Neuroprotective effects of GSK-343 in an in vivo model of MPTP-induced nigrostriatal degeneration
GSK-343 treatment preserved α-Syn accumulation. MPTP-injected mice showed an increase in the number of α-syn aggregates in substantia (B, B1, score F), compared to the Sham group (A, A1, score F). GSK-343 treatment at doses of 1 mg/kg, 5 mg/kg and 10 mg/kg revealed a reduction in the number of α-syn aggregates (C, C1, D, D1 and E, E1, score F). Data are representative of at least three independent experiments. Values are means ± SEM. One-way ANOVA test. ***p < 0.001 vs Sham; ##p < 0.01 vs MPTP; ###p < 0.001 vs MPTP